Finding a replacement for Chief Executive Officer Andrew Witty, who will retire in March after nearly a decade in the job, will be “relatively expensive,” GlaxoSmithKline Plc’s chairman said.
The U.K.’s biggest drugmaker has gotten “good value” from its executives, whose pay is at the low end of pharmaceutical industry peers, Chairman Philip Hampton said Thursday at the company’s annual general meeting in London, where Glaxo is based.
“The only candidates we would consider are people who are very seriously in the health-care sector,” Hampton told reporters in London.
The U.K.’s biggest drugmaker has gotten “good value” from its executives, whose pay is at the low end of pharmaceutical industry peers, Chairman Philip Hampton said Thursday at the company’s annual general meeting in London, where Glaxo is based.
“The only candidates we would consider are people who are very seriously in the health-care sector,” Hampton told reporters in London.
